FDA Approves Aucatzyl for Adults With Relapsed or Refractory B-Cell Precursor ALL

The FDA approved Aucatzyl, a CD19-directed genetically modified autologous T-cell immunotherapy, for adults with ...

NOVEMBER 12, 2024

FDA Grants Accelerated Approval to Iclusig With Chemotherapy for Newly Diagnosed Ph+ ALL

The FDA granted accelerated approval to Iclusig with chemotherapy for adult patients with newly diagnosed ...

MARCH 20, 2024

Obesity Plays Adverse Role in AYAs’ Response to ALL Treatment Regimens

Among adolescents and young adults being treated for acute lymphoblastic leukemia, those who are overweight or ...

SEPTEMBER 16, 2023

In Newly Diagnosed ALL, Addition of BiTE to Consolidation Therapy Improves OS

The addition of Blincyto to the consolidation regimen of patients with previously untreated B-lineage ALL provides ...

JANUARY 18, 2023

Studies Point to Optimal Dosing in Acute Leukemia and Lymphoma

New studies have yielded important clues into the optimal chemotherapy dosing schedules for acute lymphoblastic ...

JANUARY 26, 2022

Reducing Infection Risk in Young Leukemia Patients

The first few weeks is a crucial stage in monitoring and preventing infection in these children.

SEPTEMBER 14, 2017

FDA Approves Kymriah, First Gene Therapy in U.S.

CAR T-cell therapy approved to treat certain children and young adults with B-cell acute lymphoblastic leukemia.

AUGUST 31, 2017

FDA Approves Besponsa for Adults With Relapsed or Refractory ALL

Pfizer's new drug is the first and only CD22-directed antibody–drug conjugate indicated for the treatment of ...

AUGUST 17, 2017

FDA Grants New Pediatric Indication for Blincyto

Blinatumomab met its primary Phase II endpoint in 93 children with ALL of complete remission within the first two ...

OCTOBER 14, 2016